Clinical Trial: Regulation of Arginine-vasopressin (AVP)

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional




Official Title: Regulation of Arginine-vasopressin (AVP) in Psychiatric Disorders

Brief Summary: This study aims to develop a method for the assessment of central NMDA receptor functioning in patients with depression and schizophrenia. For this purpose a transitional approach is used based on preclinical studies that show a dose-dependent relationship between the activity of hypothalamic NMDA receptor and plasma AVP response to increasing plasma osmolality. Patients with schizophrenia, depression and healthy controls participated in this study. The Investigators found that in a subgroup of patients with schizophrenia the AVP response was low and that in a subgroup of subjects with depression the AVP response was high compared to healthy controls.